Literature DB >> 22334085

Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment.

Mariangela Rondanelli1, Annalisa Opizzi, Milena Faliva, Marco Mozzoni, Neldo Antoniello, Roberta Cazzola, Rita Savarè, Renata Cerutti, Enzo Grossi, Benvenuto Cestaro.   

Abstract

Age-related changes in nutritional status can play an important role in brain functioning. Specific nutrient deficiencies in the elderly may exacerbate pathological processes in the brain. Consequently, the potential of nutritional intervention to prevent or delay cognitive impairment and the development of dementia is an important topic. A randomized, double-blind, placebo-controlled trial has been performed in 25 elderly subjects (86 ± 6 years, 20 females, 5 males) with mild cognitive impairment (MCI). These subjects were randomly assigned to supplement their diet with either an oily emulsion of docosahexaenoic acid (DHA)-phospholipids containing melatonin and tryptophan (11 subjects) or a placebo (14-matched subjects) for 12 weeks. The main aim of this study was to evaluate the efficacy of the dietary supplement on cognition, by the assessment at the start and after 12 weeks of: (1) Orientation and other cognitive functions: Mini-Mental State Examination (MMSE); (2) Short-term memory: digit, verbal, and spatial span (digit span; verbal span; Corsi's test); (3) Long-term memory: Rey's auditory-verbal learning test; 'short story' test; Rey-Osterrieth complex figure (recall); (4) Attentional abilities: attentive matrices; (5) Executive functions: Weigl's sorting test; phonological fluency 'FAS'; (6) Visuo-constructional and visuo-spatial abilities: copy of simple drawings; Rey-Osterrieth complex figure (copy); (7) Language: semantic fluency; (8) Mood: Geriatric Depression Scale (GDS). Moreover, Sniffin' Sticks olfaction test and Mini Nutritional Assessment (MNA) have been performed. After 12 weeks, a significant treatment effect for the MMSE (P < 0.001) and a positive trend for the semantic verbal fluency was found in the supplement group (P < 0.06). A significant treatment effect was found out for the olfactory sensitivity assessment (P < 0.009). As regards the nutrition evaluation, after 12 weeks of treatment the supplemented group showed an improvement in the MNA score with a significant difference relative to placebo (P < 0.005). Older adults with MCI had significant improvements in several measures of cognitive function when supplemented with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan for 12 weeks, compared with the placebo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22334085     DOI: 10.1179/1476830511Y.0000000032

Source DB:  PubMed          Journal:  Nutr Neurosci        ISSN: 1028-415X            Impact factor:   4.994


  22 in total

1.  Recommendations on screening for cognitive impairment in older adults.

Authors:  Kevin Pottie; Rana Rahal; Alejandra Jaramillo; Richard Birtwhistle; Brett D Thombs; Harminder Singh; Sarah Connor Gorber; Lesley Dunfield; Amanda Shane; Maria Bacchus; Niel Bell; Marcello Tonelli
Journal:  CMAJ       Date:  2015-11-30       Impact factor: 8.262

Review 2.  Treatment for mild cognitive impairment: systematic review.

Authors:  Claudia Cooper; Ryan Li; Constantine Lyketsos; Gill Livingston
Journal:  Br J Psychiatry       Date:  2013-09       Impact factor: 9.319

3.  Nutrient biomarkers and vascular risk factors in subtypes of mild cognitive impairment: a cross-sectional study.

Authors:  Y Yin; Y Fan; F Lin; Y Xu; J Zhang
Journal:  J Nutr Health Aging       Date:  2015-01       Impact factor: 4.075

Review 4.  Omega-3 fatty acids for depression in adults.

Authors:  Katherine M Appleton; Philip D Voyias; Hannah M Sallis; Sarah Dawson; Andrew R Ness; Rachel Churchill; Rachel Perry
Journal:  Cochrane Database Syst Rev       Date:  2021-11-24

5.  Treatment for mild cognitive impairment: a systematic review and meta-analysis.

Authors:  Donna Fitzpatrick-Lewis; Rachel Warren; Muhammad Usman Ali; Diana Sherifali; Parminder Raina
Journal:  CMAJ Open       Date:  2015-12-01

6.  Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization.

Authors:  Edmond Teng; Karen Taylor; Tina Bilousova; David Weiland; Thaidan Pham; Xiaohong Zuo; Fusheng Yang; Ping-Ping Chen; Charles G Glabe; Alison Takacs; Dennis R Hoffman; Sally A Frautschy; Gregory M Cole
Journal:  Neurobiol Dis       Date:  2015-09-12       Impact factor: 5.996

7.  Effect of Omega-3 Supplementation in Patients With Smell Dysfunction Following Endoscopic Sellar and Parasellar Tumor Resection: A Multicenter Prospective Randomized Controlled Trial.

Authors:  Carol H Yan; Aakanksha Rathor; Kaelyn Krook; Yifei Ma; Melissa R Rotella; Robert L Dodd; Peter H Hwang; Jayakar V Nayak; Nelson M Oyesiku; John M DelGaudio; Joshua M Levy; Justin Wise; Sarah K Wise; Zara M Patel
Journal:  Neurosurgery       Date:  2020-08-01       Impact factor: 4.654

Review 8.  Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.

Authors:  Mariangela Rondanelli; Milena Anna Faliva; Simone Perna; Neldo Antoniello
Journal:  Aging Clin Exp Res       Date:  2013-09-18       Impact factor: 3.636

9.  Mangifera indica fruit extract improves memory impairment, cholinergic dysfunction, and oxidative stress damage in animal model of mild cognitive impairment.

Authors:  Jintanaporn Wattanathorn; Supaporn Muchimapura; Wipawee Thukham-Mee; Kornkanok Ingkaninan; Sakchai Wittaya-Areekul
Journal:  Oxid Med Cell Longev       Date:  2014-01-29       Impact factor: 6.543

10.  Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.

Authors:  Alan G Wade; Mildred Farmer; Gil Harari; Naama Fund; Moshe Laudon; Tali Nir; Anat Frydman-Marom; Nava Zisapel
Journal:  Clin Interv Aging       Date:  2014-06-18       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.